First in Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma

48 patients with chronic lymphocytic leukemia, B-cell non-Hodgkin lymphoma, or Waldenstrom’s macroglobulinemia, relapsed/refractory after ≥two prior therapies were enrolled in the open-label, single-arm, phase 1 MK-1026-001 study to receive nemtabrutinib 5 mg to 75 mg once-daily in 28-day cycles.